Clinical Trial

Identification of New Prognostic Markers for Breast Cancer.

Study acronym: PROBREAST
Recruiting
View on ClinicalTrials.gov →
Summary
Candidate markers have been identified thanks to an original approach developed by our research team aiming at detecting ectopic gene expression using public pan-genomic breast cancer data. The same approach had already been used and validated in lung tumors, leukemias and lymphomas. The main objective of the present research is to use tumor samples from patients in a retrospective and prospective cohort to test and validate the relevance of these prognostic markers in breast cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-02-15; most recent amendment 2023-02-27.
Trial Details
NCT Number NCT03436069
Lead Sponsor University Hospital, Grenoble
Conditions Breast Cancer
Enrollment 1,500 participants
Start Date 2011-01
Primary Completion 2033-12-31 (estimated)
Study Completion 2033-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-02-28